The Akkermansia Company and Metagenics to launch pasteurised healthy bacteria

By Kavitha Sivasubramaniam

- Last updated on GMT

© The Akkermansia Company
© The Akkermansia Company

Related tags The Akkermansia Company Metagenics Bacteria Pasteurization

The Akkermansia Company, formerly called A-Mansia Biotech, has revealed its new brand name along with plans to launch food supplement Akkermansia muciniphila.

The Belgian business is working with Metagenics Europe to introduce the “next-generation” of pasteurised healthy bacteria in Belgium, the Netherlands and Luxembourg this September.

Under an exclusive agreement, the micronutrition company, which is also based in Belgium, will be responsible for the distribution of the supplement across the region.

Michael Oredsson, CEO of The Akkermansia Company, says: “The distribution agreement with Metagenics is the first phase of the launch of The Akkermansia Company brand.

“We are pleased to work with the leading company in BeNeLux and look forward to announcing next steps in our international expansion soon. We are proud to have our base in Belgium and Wallonia, an ideal hub as we develop into a global company."

Weight management support

The new supplement aims to help people with weight management, as well as prevent cardiovascular disease and type II diabetes.

The Akkermansia Company, which specialises in the microbiome, finally received market authorisation from the European Commission in September 2021, following 17 years of research and development. The decision means that it is now able to sell the product across the European Union.

Stijn Oste, CEO of Metagenics Europe, ​says: “We are very proud to be the first company to sign a partnership agreement with The Akkermansia Company.

“We plan to invest in the development and management of observational studies in close collaboration with the prescribers. The products formulated with Akkermansia muciniphila pave the way for a new generation of food supplements.”

Health benefits

Discovered in 2004, the Akkermansia muciniphila​ bacterium was isolated from human intestinal microbiota and characterised by Professor Willem M. de Vos of Wageningen University, Netherlands, a co-founder of The Akkermansia Company.

The other co-founder, Professor Patrice D. Cani of UCLouvain, Bruxelles, Belgium, and his team soon helped to expose the bacterium’s beneficial effects.

The pair’s collaboration has led to many scientific publications, which includes human clinical research. They have found that pasteurised Akkermansia muciniphila​ can dramatically reduce risk factors linked to diabetes type II and cardiovascular disease, such as a lowering of liver inflammatory markers, insulin resistance and hypercholesterolemia.

The bacteria can restore intestinal barrier function, which can reduce inflammation and eventually help manage the storage of fat, energy expenditure and glucose metabolism.

In addition, the pasteurised product has been found to work better than live Akkermansia​. It also has a long shelf-life, is stable, and can be used in various types of food.

Related news

Related products

show more

Explore New Opportunities in Postbiotics

Explore New Opportunities in Postbiotics

Content provided by CJ BIO | 21-Jun-2024 | White Paper

Explore the latest trends and versatile postbiotics to propel your brand forward. As a biotics market expert, staying ahead with innovation is crucial.

Related suppliers

Follow us


View more